| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_c4f088eb5f3ddcba765f67b70fe83d63
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_ac154daa4f12eed1fdc9be78f546eeae
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_a3f545feeb02ad5f71cbd4d5e402b790
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_649205a54988c1428dcb56681a4ad46b
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_42e94091a4fc81b8d0237117707cc7ee |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-196
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P29-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2077
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-205 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-36
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P29-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-195
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-196
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-20 |
| filingDate |
1996-12-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_babb5fcb8c62883dbd1c429f86adf2cd
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_88614d37d1a8556864e80e5e1ecb0824
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_abe7f555abf30b8c53cde4c7346f5b24
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a7f183b976fcce1de738b2cf5e9b7b63 |
| publicationDate |
1997-06-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
WO-9722340-A1 |
| titleOfInvention |
Rapid release tablet comprising tolfenamic acid or a pharmaceutically acceptable salt thereof |
| abstract |
A rapid release tablet comprising an active ingredient selected from tolfenamic acid and pharmaceutically acceptable salts thereof. The active ingredient has a mean particle size of ≤ 10 νm. The tablet comprises alginic acid or a pharmaceutically acceptable salt thereof in an amount of 1.5 - 6.0 % by weight and a superdisintegrant in an amount of at least 6 % by weight. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2008156217-A2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10905694-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-6875446-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2002524493-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/AU-2008264445-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2008156217-A3
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-6521253-B1 |
| priorityDate |
1995-12-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |